Enveda joined the Unicorn Club in 2025 after raising a $150 million Series D funding round, marking a key milestone in its growth as a leading drug discovery analytics company. Headquartered in Cambridge, Massachusetts, United States, Enveda develops analytics and AI-driven platforms to accelerate the discovery of novel therapeutics.
Its platform blends computational biology, machine learning, and data analytics to identify promising drug candidates faster and more cost-effectively.
Keep reading to learn how Enveda became a $1.2 billion leader in drug-discovery analytics.
What Is Enveda and What Does It Do?
Founded in 2019, Enveda builds a drug discovery analytics platform to identify new therapeutic compounds with high precision. The company combines AI, large-scale biological data, and computational methods to speed up target identification, compound screening, and preclinical evaluation.
Enveda’s approach helps reduce the time and cost of traditional drug discovery by prioritizing high-potential candidates early in the process, accelerating the road from research to therapy.
How Much Funding Has Enveda Raised?
1. Series D Round
- Amount Raised: $150 million
- Date: 2025
- Valuation: $1.2 billion
- Lead Investors: Lux Capital, True Ventures
- Purpose: Expand analytics platform, accelerate drug-candidate discovery, and scale computational biology infrastructure
2. Earlier Rounds (Seed to Series C)
- Cumulative Funding: ~$370 million
- Key Investors: Lux Capital, True Ventures, and other biotech-oriented funds
- Purpose: Build a core analytics and AI platform, gather biological datasets, and begin preclinical workflows
Total Funding Raised: ~$520 million
Latest Funding Date: 2025
Latest Known Valuation: ~$1.2 billion
Key Investors
- Lux Capital
- Details: Venture capital firm investing in cutting-edge science and technology companies.
- Focus Areas: Biotechnology, drug discovery, advanced AI, and life-science platforms.
- True Ventures
- Details: Early-stage venture capital firm backing innovative technology and healthcare startups.
- Focus Areas: Digital health, biotech, analytics platforms, and transformative therapeutic technologies.
Where Is Enveda’s Headquarters?
Enveda is headquartered in Cambridge, Massachusetts, United States, serving as the center for its computational biology, drug-discovery analytics, and research operations.
What’s Next for Enveda?
Enveda plans to further develop its AI-driven analytics platform, expand biological data pipelines, and accelerate the discovery of novel drug candidates. The company aims to push more assets into preclinical and clinical development, leveraging its computational tools to bring new therapies to market faster.
With strong investor backing and a $1.2B valuation, Enveda is positioned to lead innovation in AI-driven drug discovery and transform how therapeutics are discovered and developed.
Get Investor and Funding Insights with TexAu
TexAu provides verified investor and funding data for companies like Enveda. Explore insights on biotech, AI-driven therapeutics, and high-growth life-science startups shaping the future of medicine.
Sign up for Free to access real-time investor and funding intelligence.
